News

After Major Oncology Conference, All Eyes Turn to Industry Innovation
After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), ...
Medical Marketing & Media5h
Rx Rundown: BioNTech, Merck, RayzeBio and more
RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...
USA News Group: After Major Oncology Conference, All Eyes Turn to Industry Innovation
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference ...
Le Lézard12h
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Inc. ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced ...
Cardinal Health raises FY25 earnings outlook on investor day
Shares of Cardinal Health (NYSE:CAH) traded higher in the premarket on Thursday after the medical distributor, in conjunction ...